Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 3
2010 1
2011 1
2013 1
2016 1
2017 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Yuan F, et al. Curr Med Res Opin. 2017 Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7. Curr Med Res Opin. 2017. PMID: 28166427
BACKGROUND: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS …
BACKGROUND: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trial …
Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
Brenner DM, Chey WD. Brenner DM, et al. Rev Gastroenterol Disord. 2009 Winter;9(1):7-15. Rev Gastroenterol Disord. 2009. PMID: 19367213 Review.
Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are strain specific. Bifidobacterium infantis 35624 ( B infantis 35624; Bifantis, The Procter & Gamble Co …
Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are …
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Whorwell PJ, et al. Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x. Am J Gastroenterol. 2006. PMID: 16863564 Clinical Trial.
Thus, not all species will necessarily have the same therapeutic potential in a particular condition. We have preliminary evidence that Bifidobacterium infantis 35624 may have utility in irritable bowel syndrome (IBS). OBJECTIVES: This study was design …
Thus, not all species will necessarily have the same therapeutic potential in a particular condition. We have preliminary evidence that B …
The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.
McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. McKernan DP, et al. Neurogastroenterol Motil. 2010 Sep;22(9):1029-35, e268. doi: 10.1111/j.1365-2982.2010.01520.x. Epub 2010 Jun 1. Neurogastroenterol Motil. 2010. PMID: 20518856
METHODS: Following 14 days oral gavage of Lactobacillus salivarius UCC118, Bifidobacterium infantis 35624, or Bifidobacterium breve UCC2003 both SD and WKY rats were exposed to a novel stress, the open field arena and their behavior was recorded. ...CO …
METHODS: Following 14 days oral gavage of Lactobacillus salivarius UCC118, Bifidobacterium infantis 35624, or Bifido …
Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic.
Charbonneau D, Gibb RD, Quigley EM. Charbonneau D, et al. Gut Microbes. 2013 May-Jun;4(3):201-11. doi: 10.4161/gmic.24196. Epub 2013 Apr 2. Gut Microbes. 2013. PMID: 23549409 Free PMC article. Clinical Trial.
Secondarily, changes in assessed fecal microbiota and IBS symptoms were determined. Supplementation significantly increased fecal B. infantis 35624 excretion vs. placebo in IBS subjects; excretion in healthy subjects receiving supplement was quantitati …
Secondarily, changes in assessed fecal microbiota and IBS symptoms were determined. Supplementation significantly increased fecal B. …
Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.
Ringel-Kulka T, McRorie J, Ringel Y. Ringel-Kulka T, et al. Am J Gastroenterol. 2017 Jan;112(1):145-151. doi: 10.1038/ajg.2016.511. Epub 2016 Nov 15. Am J Gastroenterol. 2017. PMID: 27845337 Clinical Trial.
OBJECTIVES: Bifidobacterium infantis 35624 is a probiotic that is used often in patients with irritable bowel syndrome (IBS). ...CONCLUSIONS: Unlike previous clinical studies in patients with IBS, B. infantis 35624 did not show a s …
OBJECTIVES: Bifidobacterium infantis 35624 is a probiotic that is used often in patients with irritable bowel syndrome …
The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. Brenner DM, et al. Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050. doi: 10.1038/ajg.2009.25. Epub 2009 Mar 10. Am J Gastroenterol. 2009. PMID: 19277023
None of the studies provided quantifiable data about both tolerability and adverse events. Bifidobacterium infantis 35624 showed significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficult …
None of the studies provided quantifiable data about both tolerability and adverse events. Bifidobacterium infantis 35624 …
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Maslennikov R, Gosteeva E, Ananeva V, Korshunova L, Kravtsowa A, Poluektova E, Ulyanin A, Sigidaev A, Kikhasurova P, Ivashkin V. Maslennikov R, et al. J Clin Med. 2026 Feb 2;15(3):1152. doi: 10.3390/jcm15031152. J Clin Med. 2026. PMID: 41682832 Free PMC article. Review.
Background: Many probiotic strains have been studied in relation to irritable bowel syndrome (IBS). The aim of this study was to identify probiotic strains demonstrating efficacy in the management of IBS based on meta-analyses of randomized placebo-controlled trials …
Background: Many probiotic strains have been studied in relation to irritable bowel syndrome (IBS). The aim of this study was to iden …
Review article: the treatment of functional abdominal bloating and distension.
Schmulson M, Chang L. Schmulson M, et al. Aliment Pharmacol Ther. 2011 May;33(10):1071-86. doi: 10.1111/j.1365-2036.2011.04637.x. Epub 2011 Mar 29. Aliment Pharmacol Ther. 2011. PMID: 21488913 Review.
A greater proportion of nonconstipating IBS patients reported adequate relief of bloating with rifaximin vs. placebo (40% vs. 30%, P<0.001). Bloating was significantly reduced with the probiotics, Bifidobacterium infantis 35624 (1 10(8) dose vs. pla …
A greater proportion of nonconstipating IBS patients reported adequate relief of bloating with rifaximin vs. placebo (40% vs. 30%, P& …
Do probiotics improve symptoms in patients with irritable bowel syndrome?
Whorwell PJ. Whorwell PJ. Ther Adv Gastroenterol. 2009 Jul;2(4):37-44. doi: 10.1177/1756283X09335637. Ther Adv Gastroenterol. 2009. PMID: 21180553 Free PMC article.
It has to be acknowledged that the quality and design of trials of probiotics in IBS has been somewhat variable but the majority have shown benefit, although some bacteria appear to be more effective than others. More recent studies using Bifidobacterium infantis …
It has to be acknowledged that the quality and design of trials of probiotics in IBS has been somewhat variable but the majority have …
11 results